摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[2-(6-Chloronaphthalen-1-yl)oxyethyl]morpholine | 848144-40-1

中文名称
——
中文别名
——
英文名称
4-[2-(6-Chloronaphthalen-1-yl)oxyethyl]morpholine
英文别名
——
4-[2-(6-Chloronaphthalen-1-yl)oxyethyl]morpholine化学式
CAS
848144-40-1
化学式
C16H18ClNO2
mdl
——
分子量
291.777
InChiKey
AIZUNPSLTDLYTQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    447.6±35.0 °C(Predicted)
  • 密度:
    1.212±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    21.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    甲基戊酰氯4-[2-(6-Chloronaphthalen-1-yl)oxyethyl]morpholine三氯化铝 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 以83%的产率得到Methyl 2-[7-chloro-4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetate
    参考文献:
    名称:
    The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors
    摘要:
    We have identified a novel series of potent p38 MAP kinase inhibitors through structure-based design which due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME and in vivo PK studies show these compounds to have drug-like characteristics which could result in the development of an oral treatment for inflammatory conditions. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.02.033
  • 作为产物:
    描述:
    C16H20N2O2盐酸 、 sodium nitrite 、 copper(l) chloride 作用下, 反应 2.0h, 以11%的产率得到4-[2-(6-Chloronaphthalen-1-yl)oxyethyl]morpholine
    参考文献:
    名称:
    The design and synthesis of novel α-ketoamide-based p38 MAP kinase inhibitors
    摘要:
    We have identified a novel series of potent p38 MAP kinase inhibitors through structure-based design which due to their extended molecular architecture bind, in addition to the ATP site, to an allosteric pocket. In vitro ADME and in vivo PK studies show these compounds to have drug-like characteristics which could result in the development of an oral treatment for inflammatory conditions. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.02.033
点击查看最新优质反应信息

文献信息

  • CYTOKINE INHIBITORS
    申请人:Boman Erik
    公开号:US20100093734A1
    公开(公告)日:2010-04-15
    The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.
    本发明提供了低分子量化合物,可用作细胞因子抑制剂及其组合物。特别是,本发明的化合物可用作抗炎剂。还提供了制备这种药剂的方法,以及其在预防或治疗由细胞因子介导的疾病,如关节炎方面的用途。
  • Cytokine inhibitors
    申请人:Boman Erik
    公开号:US20050107399A1
    公开(公告)日:2005-05-19
    The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions mediated by cytokines such as arthritis.
    本发明提供了低分子量化合物,作为细胞因子抑制剂以及其组合物。特别地,本发明的化合物可用作抗炎剂。此外,还提供了制备这些药剂的方法,并将它们用于预防或治疗由细胞因子介导的疾病,例如关节炎。
  • ALPHA-KETOAMIDES AND DERIVATIVES THEREOF
    申请人:Boman Erik
    公开号:US20100273797A1
    公开(公告)日:2010-10-28
    The present invention provides low molecular weight compounds useful as cytokine inhibitors, and compositions thereof. In particular, compounds of the invention are useful as anti-inflammatory agents. There are further provided methods for the preparation of such agents and their use in preventing or treating conditions medicated by cytokines such as arthritis.
    本发明提供了低分子量化合物,可用作细胞因子抑制剂及其组合物。特别地,本发明的化合物可用作抗炎剂。还提供了制备这些药剂的方法,并将其用于预防或治疗由细胞因子介导的疾病,例如关节炎。
  • EP1670787A4
    申请人:——
    公开号:EP1670787A4
    公开(公告)日:2009-04-22
  • US7749999B2
    申请人:——
    公开号:US7749999B2
    公开(公告)日:2010-07-06
查看更多